Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity

International Journal of Oncology

Volumn 45, Issue 4, 2014, Pages 1583-1593

  Nakata, Susumu ^a   Tanaka, Harunari ^a   Ito, Yuichi ^a   Hara, Masayasu ^b   Fujita, Mitsugu ^c   Kondo, Eisaku ^a   Kanemitsu, Yukihide ^d   Yatabe, Yasushi ^a   Nakanishi, Hayao ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c KINKI UNIVERSITY   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

EGFR; Gefitinib; HER3; P27; Poorly differentiated colorectal cancer

Indexed keywords

BUTYRIC ACID; CASPASE 3; CASPASE 7; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DRUG SENSITIVITY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; POORLY DIFFERENTIATED COLORECTAL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BUTYRIC ACID; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907476441     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2538     Document Type: Article

References (36)

1. Hamilton SR, Rubio CA, Vogelstein B, et al: Carcinoma of the colon and rectum. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Hamilton SR and Aaltonen LA (eds). IARC Press, Lyon, pp105-119, 2000.
2. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
3. Fodde R, Smits R and Clevers H: APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1: 55-67, 2001. (Pubitemid 33741881)
4. Arai T, Takubo K, Sawabe M and Esaki Y: Pathologic characteristics of colorectal cancer in the elderly: a retrospective study of 947 surgical cases. J Clin Gastroenterol 31: 67-72, 2000. (Pubitemid 30430251)
5. Kazama Y, Watanabe T, Kanazawa T, Tanaka J, Tanaka T and Nagawa H: Poorly differentiated colorectal adenocarcinomas show higher rates of microsatellite instability and promoter methylation of p16 and hMLH1: a study matched for T classification and tumor location. J Surg Oncol 97: 278-283, 2008. (Pubitemid 351312170)
6. Xiao H, Yoon YS, Hong SM, Roh SA, Cho DH, Yu CS and Kim JC: Poorly differentiated colorectal cancers: correlation of microsatellite instability with clinicopathologic features and survival. Am J Clin Pathol 140: 341-347, 2013.
7. Hinoi T, Tani M, Lucas PC, et al: Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol 159: 2239-2248, 2001. (Pubitemid 33104277)
8. Chung CK, Zaino RJ and Stryker JA: Colorectal carcinoma: evaluation of histologic grade and factors influencing prognosis. J Surg Oncol 21: 143-148, 1982. (Pubitemid 13250510)
9. Kawabata Y, Tomita N, Monden T, et al: Molecular characteristics of poorly differentiated adenocarcinoma and signet-ring-cell carcinoma of colorectum. Int J Cancer 84: 33-38, 1999. (Pubitemid 29059105)
10. Kim JH, Rhee YY, Bae JM, Cho NY and Kang GH: Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer. Am J Surg Pathol 37: 1532-1541, 2013.
11. Seshimo I, Yamamoto H, Mishima H, et al: Expression and mutation of SMAD4 in poorly differentiated carcinoma and signet-ring cell carcinoma of the colorectum. J Exp Clin Cancer Res 25: 433-442, 2006. (Pubitemid 44763736)
12. Rad R, Cadiñanos J, Rad L, et al: A genetic progression model of Braf (V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 24: 15-29, 2013.
13. Coffee EM, Faber AC, Roper J, et al: Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF (V600E) colorectal cancer. Clin Cancer Res 19: 2688-2698, 2013.
14. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005. (Pubitemid 40637826)
15. Oshima Y, Tanaka H, Murakami H, Ito Y, Furuya T, Kondo E, Kodera Y and Nakanishi H: Lapatinib sensitivity of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines. Gastric Cancer 17: 450-462, 2014.
16. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K and Ludwig H: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71: 2454-2460, 1993. (Pubitemid 23100476)
17. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004. (Pubitemid 38944402)
18. Chung KY, Shia J, Kemeny NE, et al: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23: 1803-1810, 2005. (Pubitemid 46211358)
19. Moroni M and Veronese S: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer. A cohort study. Lancet Oncol 6: 279-286, 2005. (Pubitemid 40590264)
20. Lievre A, Bachet JB, Le Corre D, et al: KRAS mutation is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
21. Yokota T, Ura T, Shibata N, et al: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104: 856-862, 2011.
22. Menendez JA and Lupu R: Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited? Breast Cancer Res 9: 111, 2007.
23. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM and Moasser MM: Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3. Nature 445: 437-441, 2007. (Pubitemid 46160912)
24. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S and Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132-4141, 2002. (Pubitemid 34791085)
25. Maurer CA, Friess H, Kretschmann B, et al: Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 29: 771-777, 1998. (Pubitemid 28375981)
26. Ito Y, Nakanishi H, Kodera Y, Hirai T, Nakao A and Kato T: Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV. Cancer Sci 101: 1853-1860, 2010.
27. Yokoyama H, Nakanishi H, Kodera Y, et al: Biological significance of isolated tumor cells and micrometastasis in lymph nodes evaluated using a green fluorescent protein (GFP)-tagged human gastric cancer cell line. Clin Cancer Res 12: 361-368, 2006. (Pubitemid 43166122)
28. Carrano AC, Eytan E, Hershko A and Pagano M: Skp2 is required for ubiquitin-mediated degradation of the CDK inhibitor P27. Nat Cell Biol 3: 193-199, 1999. (Pubitemid 129500937)
29. Pagano M: Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis. Mol Cell 14: 414-416, 2004.
30. Kountourakis P, Pavlakis K, Psyrri A, et al: Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6: 46, 2006.
31. Beji A, Horst D, Engel J, et al: Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res 18: 956-968, 2012.
32. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A and Amir E: HER3 overexpression and survival in solid tumors: A meta-analysis. J Natl Cancer Inst 105: 266-273, 2013.
33. Baiocchi G, Lopes A, Coudry RA, et al: ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Colorectal Dis 24: 1059-1068, 2009.
34. Coqueret O: New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13: 65-70, 2003.
35. Di Gennaro E, Barbarino M, Bruzzese F, et al: Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 195: 139-150, 2003.
36. Varna M, Lehmann-Che J, Turpin E, et al: p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer 124: 991-997, 2009.